FDA on MDMA-Assisted Psychotherapy

This page reviews the FDA’s decision not to endorse MDMA-assisted psychotherapy and explains that the agency asked for more research before a future review. It places the decision in the context of psychedelic-assisted therapies and mental health treatment. The page also outlines MDMA’s history, including its legal therapeutic use before 1985 and its later role in both recreational use and psychotherapy. It describes reported effects in supervised therapy, such as reduced symptoms of PTSD, depression, and anxiety. A final section summarizes MAPS president Rick Doblin’s response and the organization’s long-term work on reducing stigma, generating evidence, and educating the public about psychedelic-assisted therapies. The content is informational and is most relevant to readers interested in psychedelic policy, psychotherapy, and mental health research.